As filed with the Securities and Exchange Commission on March 5, 2015
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Acorda Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
13-3831168
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer Identification No.)
|
| |
|
|
|
420 Saw Mill River Road
Ardsley, New York
|
|
10502
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
2006 Employee Incentive Plan
(Full Title of the Plan)
Ron Cohen, M.D.
Chief Executive Officer
420 Saw Mill River Road
Ardsley, New York 10502
(Name and Address of Agent For Service)
(914) 347-4300
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
|
Large Accelerated Filer x
|
Accelerated o
|
|
Non-Accelerated Filer o (Do not check if a smaller reporting company)
|
Smaller Reporting Company o
|
CALCULATION OF REGISTRATION FEE
|
Title of Securities
to be Registered
|
Amount to
be Registered(1)
|
Proposed Maximum
Offering Price
Per Share (2)
|
Proposed Maximum
Aggregate
Offering Price (2)
|
Amount of
Registration Fee
|
|
2006 Employee Incentive Plan, Common Stock, $0.001 par value per share
|
1,695,585 shares
|
$34.37
|
$58,277,256
|
$6,855.80
|
(1) In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.
(2) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(h) and 457(c) of the Securities Act of 1933, as amended. The price per share and aggregate offering price are calculated on the basis of the average of the high and low prices of the Registrant’s common stock on February 27, 2015, as reported on the NASDAQ Global Market.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an aggregate of 1,695,585 shares of common stock of the Registrant to be issued pursuant to the Registrant’s 2006 Employee Incentive Plan (the “Plan”). The shares being registered hereunder represent the number of shares by which the Plan was automatically increased on January 1, 2015, as provided by the terms of the Plan.
Item 3. INCORPORATION BY REFERENCE
Pursuant to General Instruction E to Form S-8, the contents of the Registrant’s Registration Statements on Form S-8 (File Nos. 333-131846, 333-149726, 333-158085, 333-164626, 333-174785, 333-179906, 333-187091, and 333-194375), filed with the Securities and Exchange Commission on February 14, 2006, March 14, 2008, March 18, 2009, February 1, 2010, June 8, 2011, March 5, 2012, March 6, 2013, and March 6, 2014, respectively, are incorporated herein by reference.
Item 8. EXHIBITS.
The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ardsley, State of New York, on March 5, 2015.
| |
ACORDA THERAPEUTICS, INC.
|
| |
By:
|
/s/ Ron Cohen, M.D.
|
| |
|
Ron Cohen, M.D.
|
| |
|
President and Chief Executive Officer
|
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
|
Name
|
|
Title
|
Date
|
|
/s/ Ron Cohen, M.D.
|
|
President, Chief Executive Officer and
|
March 5, 2015
|
|
Ron Cohen, M.D.
|
|
Director (Principal Executive Officer)
|
|
|
/s/ Michael Rogers
|
|
Chief Financial Officer (Principal Financial Officer
|
March 5, 2015
|
|
Michael Rogers
|
|
and Principal Accounting Officer)
|
|
POWER OF ATTORNEY
We, the undersigned directors of Acorda Therapeutics, Inc., hereby severally constitute and appoint Ron Cohen our true and lawful attorney with full power to him to sign for us and in our names in the capacities indicated below, this Registration Statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as directors to enable Acorda Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorney to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
Signatures
|
|
Title
|
Date
|
|
/s/ Barry Greene
|
|
Director
|
March 5, 2015
|
|
Barry Greene
|
|
|
|
|
/s/ Peder K. Jensen, M.D.
|
|
Director
|
March 5, 2015
|
|
Peder K. Jensen, M.D.
|
|
|
|
|
/s/ John Kelley
|
|
Director
|
March 5, 2015
|
|
John Kelley
|
|
|
|
|
/s/ Sandra Panem, Ph.D.
|
|
Director
|
March 5, 2015
|
|
Sandra Panem, Ph.D.
|
|
|
|
|
/s/ Lorin J. Randall
|
|
Director
|
March 5, 2015
|
|
Lorin J. Randall
|
|
|
|
|
/s/ Steven M. Rauscher
|
|
Director
|
March 5, 2015
|
|
Steven M. Rauscher
|
|
|
|
|
/s/ Ian F. Smith
|
|
Director
|
March 5, 2015
|
|
Ian F. Smith
|
|
|
|
INDEX TO EXHIBITS
|
Number
|
|
Description
|
|
5.1
|
|
Opinion of Covington & Burling LLP, counsel to the Registrant
|
| |
|
|
|
23.1
|
|
Consent of Covington & Burling LLP (included in Exhibit 5.1)
|
| |
|
|
|
23.2
|
|
Consent of Ernst & Young LLP
|
| |
|
|
|
24.1
|
|
Power of Attorney of all directors of the board of directors of the Registrant (included on the signature pages of this registration statement)
|
EXHIBIT 5.1
March 5, 2015
Acorda Therapeutics, Inc.
420 Saw Mill River Road
Ardsley, New York 10502
Ladies and Gentlemen:
We have acted as counsel to Acorda Therapeutics, Inc., a Delaware corporation (the “Company”), in connection with the registration by the Company under the Securities Act of 1933, as amended (the “Act”), of 1,695,585 shares of the Company’s Common Stock, par value $0.001 per share (the “Shares”), issuable under the Company’s 2006 Employee Incentive Plan (as amended, the “Plan”), pursuant to the registration statement on Form S-8 filed with the Securities and Exchange Commission on March 5, 2015 (such registration statement is referred to herein as the “Registration Statement”).
We have reviewed such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purposes of this opinion. We have assumed that all signatures are genuine, that all documents submitted to us as originals are authentic and that all copies of documents submitted to us conform to the originals.
We have relied as to certain matters on information obtained from public officials, officers of the Company and other sources believed by us to be responsible.
Based upon the foregoing, we are of the opinion that the Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Company’s Certificate of Incorporation, the Plan and any individual agreements relating to such Shares, will be validly issued, fully paid and nonassessable.
We are members of the bar of the State of New York. We do not express any opinion herein on any laws other than the General Corporation Law of the State of Delaware and applicable provisions of the Delaware Constitution and reported judicial decisions interpreting these laws.
We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act.
Sincerely,
/s/ Covington & Burling LLP
EXHIBIT 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement pertaining to the 2006 Employee Incentive Plan of Acorda Therapeutics, Inc. of our reports dated February 27, 2015, with respect to the consolidated financial statements of Acorda Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Acorda Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2014, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
MetroPark, New Jersey
February 27, 2015
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024
